AGP Picks
View all

AGP Executive Report

Last update: 2 hours ago

Vaccine Trial: A revised hepatitis B study involving 14,000 newborns in Guinea-Bissau has received new ethics approvals. Half the infants would get the vaccine at birth; the rest would wait until six weeks. The protocol excludes babies whose mothers test positive, but critics say delaying protection remains risky, and final national authorization is still reported as pending. Election Delay: The military authorities say conditions are not in place for the December 6 elections, with no new date announced. ECOWAS is urging broad, transparent talks on a revised timetable, as the delay deepens doubts over the junta’s promise to restore civilian rule.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
Oct. 8, 2026

Stand Up for Science blasts CDC plan to revive Guinea-Bissau vaccine study

AGP

fallback image
Sep. 7, 2026

ROX opens Abu Dhabi AI manufacturing center, starts local vehicle production

AGP

fallback image
Aug. 21, 2026

Senegal backs MSGBC Oil, Gas & Power 2026 in Dakar

AGP

fallback image
Aug. 21, 2026

Senegal’s president backs MSGBC Oil, Gas & Power 2026 in Dakar

AGP


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate Press Release Service
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Press Release Service
Danish University Approves CDC-Funded Trial That Would Delay Hepatitis B Shots for Half of 14,000 Newborns in Guinea-Bissau

Danish University Approves CDC-Funded Trial That Would Delay Hepatitis B Shots for Half of 14,000 Newborns in Guinea-Bissau


fallback image
Oct. 8, 2026

Stand Up for Science Condemns CDC’s Attempts to Restart Controversial Vaccine Study in Guinea-Bissau

EIN Presswire

fallback image
Oct. 12, 2026

Countries locked into IMF austerity programs are also around twice as vulnerable to economic fallout from war against Iran

Oxfam

fallback image
Sep. 4, 2026

Đurić Confers with Guinea-Bissau’s Minister of Foreign Affairs

Ministry of Foreign Affairs of the Republic of Serbia

fallback image
Sep. 2, 2026

Đurić Confers with Guinea-Bissau’s Minister of Foreign Affairs

Ministry of Foreign Affairs of the Republic of Serbia

fallback image
Feb. 22, 2026

Guinea-Bissau Stops Trump-Backed Hepatitis B Vaccine Study

MENAFN

fallback image
Feb. 22, 2026

Guinea-Bissau Stops US-Funded Hepatitis B Vaccine Trial

MENAFN

More press releases

Video Stories

YouTube video thumbnail: Guinea-Bissau Elections in Doubt as Senegal Urges Military to Ease Restrictions
Play
Guinea-Bissau Elections in Doubt as Senegal Urges Military to Ease Restrictions
YouTube video thumbnail: Eritrea Urges United Nations to Intervene in Standoff With Ethiopia
Play
Eritrea Urges United Nations to Intervene in Standoff With Ethiopia
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail: Ethiopian Official Promises Change in Tigray After Troops Retake Regional Capital
Play
Ethiopian Official Promises Change in Tigray After Troops Retake Regional Capital
YouTube video thumbnail:  Nigeria Pushes EVs, but Where Will Drivers Charge?
Play
Nigeria Pushes EVs, but Where Will Drivers Charge?

Video Title

Sign up for:

Guinea Bissau Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Guinea Bissau Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.